FGFR2 and cholangiocarcinoma: Infigratinib is under evaluation in a phase III study as first-line treatment for patients with cholangiocarcinoma and FGFR2 gene fusions/translocations (ClinicalTrials.gov Identifier: NCT03773302) and in a phase I study in patients with high-grade glioma and FGFR3–TACC3 translocations (ClinicalTrials.gov Identifier: NCT04424966).